- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06433635
Sequential Multiple Assignment Randomized Trial for Bipolar Depression (SMART-BD)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a comparative effectiveness study to address the critical questions of how best to treat people with bipolar disorder who have a major depressive episode: how to get them well, provide second-line treatment when they don't initially get well, and keep them well after they get well. This is a multisite Sequential Multiple Assignment Randomized Trial (SMART) comparative effectiveness design. Investigators will recruit 2726 participants who have BD with a current major depressive episode. In Stage 1, investigators will compare four treatment arms, including three FDA approved monotherapies and the most widely used, but understudied, treatment for BD major depressive episode (i.e., a non-FDA approved combination of an antipsychotic and antidepressant). In Stage 2, participants who do not remit will be re-randomized to treatments not used in Stage 1. Investigators will follow all participants for a total of 52 weeks. This study will be conducted in two phases, a feasibility phase and a full study phase. In the feasibility phase, investigators will recruit at 8 of the 19 study sites based on readiness and interest, to ensure the efficacy of the study design before launching the full study phase.
Feasibility Aim 1: To ensure that 8 of the 19 selected sites can recruit, randomize, and retain participants. During the feasibility phase, the selected sites will recruit 133 participants, administer baseline assessments, randomize the participants (at baseline and again at 6-weeks for non-remitters), and conduct follow-up assessments at the end of Stage 1 (6-weeks) and the end of Stage 2 (12-weeks) and end of study (52 weeks or end of feasibility phase, whichever is sooner) and all other scheduled visits.
Feasibility Aim 2: To refine and finalize all study standard operating procedures for the full-scale study. After Aim 1 is complete, any changes in standard operating procedures will be made as needed to be implemented in the full study phase.
Full Scale Study Full-Scale Study Aim 1: To compare the effectiveness, tolerability, and safety of the four treatments for BD major depressive episodes.
Hypothesis 1a: There will be significant differences across the Stage 1 treatments in the proportion of remitters at week 6 (primary endpoint, effectiveness) and in the average adverse event burden and suicidal ideation/behavior at week 6 (secondary endpoints, tolerability and safety).
Hypothesis 1b: Among non-remitters of a given Stage 1 treatment (i.e., participants who do not remit by week 6), there will be significant differences across the three remaining Stage 2 treatments in the proportion of remitters at week 12 (primary endpoint, effectiveness) and the average side effect burden and suicidal ideation/behavior at week 12 (secondary endpoints, tolerability and safety).
Full-Scale Study Aim 2: To characterize the effectiveness, tolerability, and safety of the 12 adaptive interventions for BD major depressive episodes embedded within the SMART design.
Hypothesis 2: On average, there will be significant differences across the 12 embedded adaptive interventions in the proportion of remitters at week 12 (primary endpoint, effectiveness) and in the average side effect burden and suicidal ideation/behavior at week 12 (secondary endpoints, tolerability and safety).
Full-Scale Study Aim 3: To determine individual-level characteristics that predict heterogeneity of treatment effect (HTE) across the 12 adaptive interventions for BD major depressive episodes embedded within the SMART design.
Hypothesis 3a: Individual-level characteristics and symptoms assessed at baseline as well as symptom changes and side effect profiles at week 6 will predict HTE at weeks 12 and 52. Hypothesis 3b: Investigators hypothesize that an optimal personalized adaptive intervention will perform significantly better than the best aggregate embedded adaptive intervention identified in Aim 2 in terms of the proportion of remitters at week 12 (primary endpoint, effectiveness) and the side effect burden and suicidal ideation/behavior at week 12 (secondary endpoints, tolerability and safety).
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Andrew Nierenberg, M.D
- Phone Number: 617-724-0837
- Email: anierenberg@mgh.harvard.edu
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6T 1Z4
- University of British Columbia
-
Contact:
- Nazlin Walji
- Email: nazlin.walji@ubc.ca
-
Principal Investigator:
- Lakshmi Yatham
-
-
Ontario
-
Toronto, Ontario, Canada, M5R 0A3
- University of Toronto
-
Contact:
- Lee Phan
- Email: lee.phan@mail.utoronto.ca
-
Principal Investigator:
- Roger McIntyre
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama Birmingham
-
Principal Investigator:
- Richard Shelton
-
Contact:
- Samanta White
- Email: swwhite@uabmc.edu
-
Principal Investigator:
- Matthew Macaluso
-
-
Maryland
-
Baltimore, Maryland, United States, 21204
- Sheppard Pratt Health System
-
Contact:
- Audrey Shoultz
- Email: audrey.shoultz@sheppardpratt.org
-
Principal Investigator:
- Scott Aaronson
-
Baltimore, Maryland, United States, 21218
- John Hopkins
-
Principal Investigator:
- Fernando Goes
-
Contact:
- Heather Klohr
- Email: hklohr1@jhmi.edu
-
-
Massachusetts
-
Belmont, Massachusetts, United States, 02478
- Mclean Hospital
-
Contact:
- Jenny Clark
-
Principal Investigator:
- Dost Ongur
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Contact:
- Khadija Tlaiti
- Phone Number: 617-584-3285
- Email: ktlaiti@mgh.harvard.edu
-
Principal Investigator:
- Masoud Kamali
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
Contact:
- Jacqui Grisdale
- Email: grisdale@umich.edu
-
Principal Investigator:
- Sagar Parikh
-
Principal Investigator:
- Melvin McInnis
-
-
Minnesota
-
Rochester, Minnesota, United States, 55902
- Mayo Clinic
-
Contact:
- Michelle Skime
- Email: skime.michelle@mayo.edu
-
Principal Investigator:
- Mark Frye
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87131-0001
- University of New Mexico Health Sciences Center Albuquerque
-
Contact:
- Josh Corb
- Email: joshcorb@salud.unm.edu
-
Principal Investigator:
- Mauricio Tohen
-
-
New York
-
New York, New York, United States, 10016
- New York University Grossman School of Medicine NYU
-
Contact:
- Xiaotong Song
- Email: xiaotong.song@nyulangone.org
-
Contact:
- Dan Iosifescu
- Email: dan.iosifescu@nyulangone.org
-
Principal Investigator:
- Dan Iosifescu
-
New York, New York, United States, 10461
- Montefiore Medical Center and Albert Einstein College of Medicine
-
Contact:
- Jennifer Alexander
- Email: jealexan@montefiore.org
-
Principal Investigator:
- Thomas Betzler
-
Principal Investigator:
- Jonathan Alpert
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina At Chapel Hill
-
Contact:
- Amanda Teer
- Email: amanda_teer@med.unc.edu
-
Principal Investigator:
- Bradley Gaynes
-
-
Ohio
-
Cleveland, Ohio, United States, 44106-1712
- Case Western Reserve University
-
Contact:
- Carla Conroy
- Email: carla.conroy@uhhospitals.org
-
Principal Investigator:
- Keming Gao
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
Contact:
- Anita Agarwal
- Email: anitaag@pennmedicine.upenn.edu
-
Principal Investigator:
- Michael Thase
-
Pittsburgh, Pennsylvania, United States, 15260
- University of Pittsburgh
-
Contact:
- Elizabeth Yute
- Email: yuteea2@upmc.edu
-
Principal Investigator:
- Holly Swartz
-
-
Texas
-
Austin, Texas, United States, 78712
- University of Texas at Austin
-
Contact:
- Lindsey Demeritt
- Email: dellmedspa@austin.utexas.edu
-
Principal Investigator:
- Jorge Almeida
-
Dallas, Texas, United States, 75390-7208
- University of Texas at Southwestern Medical Center
-
Contact:
- Lezlie Britton
- Email: lezlie.britton@utsouthwestern.edu
-
Principal Investigator:
- Madhukar Trivedi
-
Principal Investigator:
- Manish Jha
-
Houston, Texas, United States, 77030
- UT Health Houston Texas
-
Contact:
- Chelsea Tran
- Email: Chelsea.Tran@uth.tmc.edu
-
Contact:
- Courteny Vecera
- Email: courtney.vecera@uth.tmc.edu
-
Principal Investigator:
- Giovana Zunta-Soares
-
Principal Investigator:
- Jair Soares
-
Principal Investigator:
- Rodrigo MachadoVeira
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged between 18 years to 75 years
- Meets criteria for DSM-V Bipolar I disorder with a history of manic episodes and current major depressive episode lasting at least 6 weeks
- Can be managed as an outpatient and participate in the study
- Willing to be randomized; able to perform study assessments
- Women of childbearing potential must agree to use adequate contraception (e.g. oral contraceptives, intrauterine device, barrier methods, or total abstinence; Depo Provera is acceptable if it is started 3 months prior to enrollment), and inform staff of their plans to conceive.
Exclusion Criteria:
- Meets current criteria for a manic episode, rapid cycling within the past year (history of 4 or more mood episodes per year)
- History of schizophrenia or other nonaffective psychosis
- Current substance use disorder that will interfere with participation in the study
- Currently taking the study medications or a history of serious adverse events to any of the study medications, to the extent that as determined by site PI, another trial would not be clinically indicated
- A history of non-response for depressive episodes, to any of the study medications, when given at adequate doses for at least 6 weeks
- Current acute suicidal risk that requires inpatient treatment
- Pregnancy or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lurasidone
|
Other Names:
|
Experimental: Cariprazine
|
Other Names:
|
Experimental: Quetiapine
|
Other Names:
|
Experimental: Aripiprazole /Escitalopram combination
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Remission from Depression Questionnaire
Time Frame: Investigators will administer this measure every 2 weeks for the first 12 weeks (weeks:0,2,4,6,8,10,12), and then at each study visit during the follow up phase until they are discharged from the study (weeks:20,28,36,44,52 ).
|
RDQ is a 41 items self report questionnaire used to assess the seven domains found in extensive previous research to be important to patients: depressive symptoms, anxiety, coping ability, positive mental health, functioning, life satisfaction and a general sense of well-being. Using a score of 27 as the cutoff, the RDQ scale has a sensitivity of 83.7% and specificity of 77.9% in predicting self-reported remission status. The RDQ has excellent internal consistency reliability (Cronbach's alpha of 0.97 for the total scale and above 0.80 for each of the 7 subscales with test-retest reliability of the total scale = 0.85 and > 0.60 for each subscale). The primary outcome will be remission as defined by a RDQ score < 27. This test will be administered in all assessment visits. The RDQ scale ranges from 0-27 per domain, with higher scores indicating greater remission rates. |
Investigators will administer this measure every 2 weeks for the first 12 weeks (weeks:0,2,4,6,8,10,12), and then at each study visit during the follow up phase until they are discharged from the study (weeks:20,28,36,44,52 ).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety: Concise Health Risk Tracking Scale
Time Frame: Investigators will administer this measure every 2 weeks for the first 12 weeks (weeks:0,2,4,6,8,10,12), and then at each study visit during the follow up phase until they are discharged from the study (weeks:20,28,36,44,52 ).
|
CHRT is a 14 item self-report measure of suicidal ideation and behavior in individuals with mood disorders. The CHRT has excellent psychometric properties, with an internal consistency reliability (Cronbach's alpha) of 0.78 and a consistent factor structure with 3 independent factors (current suicidal thoughts and plans, perceived lack of social support, and hopelessness). The range is from 14-70, higher scores reflect an increase in suicidality behaviors. |
Investigators will administer this measure every 2 weeks for the first 12 weeks (weeks:0,2,4,6,8,10,12), and then at each study visit during the follow up phase until they are discharged from the study (weeks:20,28,36,44,52 ).
|
Frequency and Intensity of Side Effects Ratings - Intensity
Time Frame: Investigators will administer this measure every 2 weeks for the first 12 weeks (weeks:0,2,4,6,8,10,12), and then at each study visit during the follow up phase until they are discharged from the study (weeks:20,28,36,44,52 ).
|
This subscale of the FIBSER scale is a reliable self-report measure of the intensity of side effects from medications in a population receiving treatment for depression. This scale measures the participants side effects intensity from the previous week and has them rate each on a scale from 0-6. The results will help the clinician determine the appropriate level of response. The range is from 0-6, higher scores reflect an greater intensity in medication side effects. |
Investigators will administer this measure every 2 weeks for the first 12 weeks (weeks:0,2,4,6,8,10,12), and then at each study visit during the follow up phase until they are discharged from the study (weeks:20,28,36,44,52 ).
|
Frequency and Intensity of Side Effects Ratings - Frequency
Time Frame: Investigators will administer this measure every 2 weeks for the first 12 weeks (weeks:0,2,4,6,8,10,12), and then at each study visit during the follow up phase until they are discharged from the study (weeks:20,28,36,44,52 ).
|
This subscale of the FIBSER scale is a reliable and valid self-report measure on the frequency of medication side effects in a population receiving treatment for depression. This scale measures the participants side effects frequency from the previous week and has them rate each on a scale from 0-6. The results will help the clinician determine the appropriate level of response. The range is from 0-6, higher scores reflect an greater frequency in medication side effects. |
Investigators will administer this measure every 2 weeks for the first 12 weeks (weeks:0,2,4,6,8,10,12), and then at each study visit during the follow up phase until they are discharged from the study (weeks:20,28,36,44,52 ).
|
Frequency and Intensity of Side Effects Ratings - Burden
Time Frame: Investigators will administer this measure every 2 weeks for the first 12 weeks (weeks:0,2,4,6,8,10,12), and then at each study visit during the follow up phase until they are discharged from the study (weeks:20,28,36,44,52 ).
|
This subscale of the FIBSER scale is a reliable self-report measure of the side effects burden of medications in a population receiving treatment for depression. This scale measures the participants side effects burden from the previous week and has them rate each on a scale from 0-6. The results will help the clinician determine the appropriate level of response. The range is from 0-6, higher scores reflect an greater burden in medication side effects. |
Investigators will administer this measure every 2 weeks for the first 12 weeks (weeks:0,2,4,6,8,10,12), and then at each study visit during the follow up phase until they are discharged from the study (weeks:20,28,36,44,52 ).
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Altman Self-Rating Mania Scale
Time Frame: Investigators will administer this measure every 2 weeks for the first 12 weeks (weeks:0,2,4,6,8,10,12), and then at each study visit during the follow up phase until they are discharged from the study (weeks:20,28,36,44,52 ).
|
self-rating mania scale designed to assess the presence and/or severity of manic symptoms in children and adolescents The range is from 5-25, higher scores reflect increased symptoms of of mania |
Investigators will administer this measure every 2 weeks for the first 12 weeks (weeks:0,2,4,6,8,10,12), and then at each study visit during the follow up phase until they are discharged from the study (weeks:20,28,36,44,52 ).
|
Generalized Anxiety Disorder Assessment
Time Frame: Investigators will administer this measure every 2 weeks for the first 12 weeks (weeks:0,2,4,6,8,10,12), and then at each study visit during the follow up phase until they are discharged from the study (weeks:20,28,36,44,52 ).
|
A seven-item instrument that is used to measure or assess the severity of generalized anxiety disorder (GAD). The range is from 0-21, higher scores reflect increased symptoms of of anxiety |
Investigators will administer this measure every 2 weeks for the first 12 weeks (weeks:0,2,4,6,8,10,12), and then at each study visit during the follow up phase until they are discharged from the study (weeks:20,28,36,44,52 ).
|
Medication Reconciliation Tracking Form
Time Frame: Investigators will administer this measure every 2 weeks for the first 12 weeks (weeks:0,2,4,6,8,10,12), and then at each study visit during the follow up phase until they are discharged from the study (weeks:20,28,36,44,52 ).
|
The MRTF generates the average number of necessary clinical adjustments per month, which provides a method to compare long-term outcomes in a pragmatic trial. There is no range or scoring necessary for this assessment. |
Investigators will administer this measure every 2 weeks for the first 12 weeks (weeks:0,2,4,6,8,10,12), and then at each study visit during the follow up phase until they are discharged from the study (weeks:20,28,36,44,52 ).
|
Patient Health Questionnaire
Time Frame: Investigators will administer this measure every 2 weeks for the first 12 weeks (weeks:0,2,4,6,8,10,12), and then at each study visit during the follow up phase until they are discharged from the study (weeks:20,28,36,44,52 ).
|
The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression The range is from 0-27, higher scores reflect increased symptoms of of depression |
Investigators will administer this measure every 2 weeks for the first 12 weeks (weeks:0,2,4,6,8,10,12), and then at each study visit during the follow up phase until they are discharged from the study (weeks:20,28,36,44,52 ).
|
PROMIS Item Bank v2.0 Cognitive Functioning- Short Form
Time Frame: Investigators will administer this measure at baseline (week 0), week 6, and week 12. Then at each study visit during the follow up phase until they are discharged from the study (weeks:20,28,36,44,52 ).
|
Cognitive deficits will be assessed with the PROMIS- Cognitive Function-Short Form. This 8-item self-report questionnaire has good construct validity and psychometric properties and has been used as an outcome in multiple studies. The range is from 8-40, increased scores are associated with a person's increased perception of cognitive function in areas such as concentration, memory, and mental acuity |
Investigators will administer this measure at baseline (week 0), week 6, and week 12. Then at each study visit during the follow up phase until they are discharged from the study (weeks:20,28,36,44,52 ).
|
PROMIS Item Bank v2.0 Satisfaction with Social Roles and Activities
Time Frame: Investigators will administer this measure at baseline (week 0), week 6, and week 12. Then at each study visit during the follow up phase until they are discharged from the study (weeks:20,28,36,44,52 ).
|
This measure is an 8 item self-report questionnaire that assesses the individual's satisfaction with social roles and activities. The measure has clinical validity across a range of chronic conditions, including depression and responds to change in clinical state The range is from 8-40 increased scores are associated with higher feelings of satisfaction with performing one's usual social roles and activities |
Investigators will administer this measure at baseline (week 0), week 6, and week 12. Then at each study visit during the follow up phase until they are discharged from the study (weeks:20,28,36,44,52 ).
|
Young Mania Rating Scale
Time Frame: Investigators can administer at any time between weeks 0 to 52. This assessment only applies if patients has a pseudo-remission from depression, indicated if the patient scores a 6 or higher on the self-rated Altman Scale for Rating Mania (ASRM)
|
The YMRS is a rating scale used to evaluate manic symptoms at baseline and over time in individuals with mania. The range is from 0-60, higher scores reflect increased risk for Bipolar Disorder. If the participant scores 18 or above on the YMRS, they will be considered manic and not in remission even if they meet criteria for remission with the RDQ |
Investigators can administer at any time between weeks 0 to 52. This assessment only applies if patients has a pseudo-remission from depression, indicated if the patient scores a 6 or higher on the self-rated Altman Scale for Rating Mania (ASRM)
|
Quality of Life Scale
Time Frame: Investigators will administer this measure at baseline (week 0), week 6, and week 12. Then at each study visit during the follow up phase until they are discharged from the study (weeks:20,28,36,44,52 ).
|
The QoL.BD93,94 measures 12 core domains (physical, sleep, mood, cognition, leisure, social, spirituality, finances, household, self-esteem, independence, identity) and 2 optional (work, education) domains A brief 12-item version represents the core QoL domains and is scored on a five-point range (1: strongly disagree to 5: strongly agree). The range of scoring is 12-60 with higher scores reflecting a greater belief in ones quality of life. |
Investigators will administer this measure at baseline (week 0), week 6, and week 12. Then at each study visit during the follow up phase until they are discharged from the study (weeks:20,28,36,44,52 ).
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Mood Disorders
- Bipolar and Related Disorders
- Depression
- Depressive Disorder
- Bipolar Disorder
- Physiological Effects of Drugs
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Dopamine Agonists
- Dopamine Agents
- Serotonin 5-HT1 Receptor Agonists
- Serotonin Receptor Agonists
- Serotonin 5-HT2 Receptor Antagonists
- Serotonin Antagonists
- Dopamine D2 Receptor Antagonists
- Dopamine Antagonists
- Adrenergic alpha-Antagonists
- Adrenergic alpha-2 Receptor Antagonists
- Selective Serotonin Reuptake Inhibitors
- Aripiprazole
- Quetiapine Fumarate
- Lurasidone Hydrochloride
- Cariprazine
- Escitalopram
Other Study ID Numbers
- 2024P000831
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Lawson Health Research InstituteTerminated
Clinical Trials on Cariprazine
-
Gedeon Richter Plc.Completed
-
Mitsubishi Tanabe Pharma CorporationCompleted
-
AbbVieWithdrawnGeneralized Anxiety DisorderUnited States
-
Whanin Pharmaceutical CompanyEnrolling by invitationSchizophreniaKorea, Republic of
-
Forest LaboratoriesGedeon Richter Ltd.Completed
-
AbbVieRecruitingSchizophrenia | Bipolar I Disorder | Autism Spectrum Disorder (ASD)United States, Puerto Rico
-
Forest LaboratoriesGedeon Richter Ltd.CompletedBipolar DisorderUnited States
-
Forest LaboratoriesGedeon Richter Ltd.CompletedMajor Depressive DisorderUnited States
-
Kyle KampmanNational Institute on Drug Abuse (NIDA)RecruitingOpioid-use Disorder | Cocaine Use DisorderUnited States
-
Anna Rose Childress, Ph.D.National Institute on Drug Abuse (NIDA)TerminatedCocaine Use DisorderUnited States